
|Articles|February 1, 2004
Inspirational biologics
Waikoloa, Hawaii - Psoriatic patients responding to efalizumab (Raptiva, Genentech Inc. and Xoma Ltd.) biologic medication are happy with the results after an extended period of continuous treatment.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
5











